News > Huma collaborates with Bayer to advance precision treatment for lung cancer

Huma collaborates with Bayer to advance precision treatment for lung cancer

Healthtech company Huma and the life sciences company Bayer will use machine learning to try to improve diagnosis for certain types of lung cancer, by more precise readings of CT (Computed Tomography) scans.

Dan Vahdat, CEO and Founder of Huma, said "We want to start by providing more personalised care for people with non-small cell lung cancer. In the future, our vision is to include other cancers and even other therapeutic areas such as rare diseases."